,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2016-01-26 09:24:00,"Healthcare giant Johnson & Johnson has worked hard to establish itself as the preeminent conglomerate in the industry, using its exposure to pharmaceuticals, medical devices, and over-the-counter consumer remedies to its best advantage.",0.9017008543014526,0.01522231288254261,0.08307676017284393,positive,0.8864785432815552
1,2016-01-26 09:24:00,"Yet like consumer giant Procter & Gamble , J&J has struggled recently because of the strong U.S. dollar, which has weighed on both companies' ability to grow sales and earnings.",0.03329700604081154,0.9507486820220947,0.015954267233610153,negative,-0.9174516797065735
2,2016-01-26 09:24:00,"Coming into Tuesday's fourth-quarter financial report, investors in Johnson & Johnson expected to see some downward pressure on revenue, and the company did a good job of overcoming those pressures to produce bottom-line growth for the quarter.",0.9004126191139221,0.06083851680159569,0.03874889388680458,positive,0.8395740985870361
3,2016-01-26 09:24:00,"Still, with full-year sales and adjusted earnings per share falling, J&J investors want the company to do more in 2016.",0.021946046501398087,0.9396519064903259,0.038402050733566284,negative,-0.9177058339118958
4,2016-01-26 09:24:00,Let's look more closely at Johnson & Johnson and what its latest results say about its prospects over the coming year.,0.05164903402328491,0.006028173957020044,0.9423227310180664,neutral,0.045620858669281006
5,2016-01-26 09:24:00,"The same trends that investors have seen throughout 2015 showed up in Johnson & Johnson's fourth-quarter report, but arguably not to the same extent as in past quarters.",0.18866218626499176,0.07637157291173935,0.7349662780761719,neutral,0.11229061335325241
6,2016-01-26 09:24:00,"Revenue for the quarter once again fell year-over-year, but only by 2.4% to $17.8 billion.",0.01710912212729454,0.9732930064201355,0.009597869589924812,negative,-0.956183910369873
7,2016-01-26 09:24:00,"The company's bottom line actually jumped 28% to $3.22 billion, largely due to a nearly $2.2 billion swing in its other income/expense line.",0.9498865604400635,0.0224009957164526,0.02771240472793579,positive,0.9274855852127075
8,2016-01-26 09:24:00,"Even after adjusting for one-time items, earnings of $1.44 per share topped analysts' consensus forecast by $0.02.",0.9239782094955444,0.04623808339238167,0.029783722013235092,positive,0.8777401447296143
9,2016-01-26 09:24:00,Yet the strenthening U.S. dollar continued to weigh on Johnson & Johnson.,0.05812680721282959,0.8925613164901733,0.04931189864873886,negative,-0.8344345092773438
10,2016-01-26 09:24:00,"The company said that its quarterly revenue took a hit of 6.8 percentage points from currency issues, wiping out a 4.4% operational gain in sales.",0.036451637744903564,0.9509665369987488,0.012581809423863888,negative,-0.9145148992538452
11,2016-01-26 09:24:00,"Although domestic sales rose 8%, international sales plunged 11.7%, thanks to 13 percentage points of downward pressure from the strong dollar.",0.024135643616318703,0.9670642018318176,0.008800169453024864,negative,-0.9429285526275635
12,2016-01-26 09:24:00,"After factoring out currencies, hepatitis C-related sales, and one-time items like acquisitions and divestitures, its worldwide sales were actually up 6.5%.",0.9537814259529114,0.021835599094629288,0.02438301406800747,positive,0.93194580078125
13,2016-01-26 09:24:00,"Among J&J's three main business units, the pharmaceutical segment was the only one to show growth in dollar terms, edging up 0.8% thanks in large part to a nearly 13% rise in U.S. sales.",0.9542731642723083,0.0215542521327734,0.0241725891828537,positive,0.9327189326286316
14,2016-01-26 09:24:00,"The medical devices unit was relatively strong in the U.S., rising 6.7% domestically, but weak international results pulled the unit's overall sales down 3.3%.",0.022363584488630295,0.9657819271087646,0.011854523792862892,negative,-0.9434183239936829
15,2016-01-26 09:24:00,"The consumer segment brought up the rear with declines both worldwide and domestically, adding up to a 7.9% drop in overall revenues for the unit.",0.018971454352140427,0.9721387028694153,0.008889829739928246,negative,-0.9531672596931458
16,2016-01-26 09:24:00,"Those consumer results were consistent with the sales declines that Procter & Gamble reported in its latest quarter, stemming in part from currency issues but also reflecting challenges in organic growth.",0.02904062718153,0.9561113119125366,0.014848093502223492,negative,-0.927070677280426
17,2016-01-26 09:24:00,Johnson & Johnson pointed to several winning product lines.,0.7686412930488586,0.01645941659808159,0.21489928662776947,positive,0.752181887626648
18,2016-01-26 09:24:00,"Over-the-counter drugs Tylenol and Motrin helped the consumer segment, and J&J once again called out diabetes drug Invokana and plaque-psoriasis treatment Stelara as helping its sales growth in the pharmaceutical arena.",0.9309679865837097,0.017960844561457634,0.05107108876109123,positive,0.9130071401596069
19,2016-01-26 09:24:00,"In medical devices, the company benefited from sales of endocutters and biosurgical products, as well as insulin pump products and various cardiovascular and orthopedic devices.",0.5691850185394287,0.009347625076770782,0.4214673638343811,positive,0.5598374009132385
20,2016-01-26 09:24:00,"For the full year, J&J's sales fell 5.7% to $70.1 billion, with currency issues costing it 7.5 percentage points of growth.",0.017578786239027977,0.9736652374267578,0.008756015449762344,negative,-0.9560864567756653
21,2016-01-26 09:24:00,"Adjusted net income also fell to $17.4 billion, dropping almost 5% and producing adjusted earnings of $6.20 per share.",0.016420850530266762,0.9743563532829285,0.009222829714417458,negative,-0.9579355120658875
22,2016-01-26 09:24:00,"CEO Alex Gorsky characterized 2015 as providing ""strong underlying growth"" despite currency headwinds.",0.9458755254745483,0.015138518065214157,0.03898587450385094,positive,0.9307370185852051
23,2016-01-26 09:24:00,"Gorsky says he remains convinced that 2016 will keep positive momentum going, arguing that ""our core business is very healthy, and the recent decisive actions we've taken in support of each of our businesses position us well to drive sustainable long-term growth.""",0.9264063835144043,0.0153508884832263,0.05824272334575653,positive,0.9110555052757263
24,2016-01-26 09:24:00,"Johnson & Johnson's guidance made it clear, though, that the robust dollar will continue to play a key role in holding back growth.",0.8538488149642944,0.023798858746886253,0.12235232442617416,positive,0.8300499320030212
25,2016-01-26 09:24:00,"The company predicted that 2016 sales will come in between $70.8 billion and $71.5 billion, up 2.5% to 3.5% on an operational basis, but implying a roughly two percentage point hit from currencies.",0.9505922794342041,0.026059817522764206,0.023347921669483185,positive,0.9245324730873108
26,2016-01-26 09:24:00,"Similarly, adjusted 2016 earnings of $6.43 to $6.58 per share would be up 5.3% to 7.7% on an operational basis.",0.953080952167511,0.019777188077569008,0.027141842991113663,positive,0.9333037734031677
27,2016-01-26 09:24:00,One key aspect to J&J's future is how its restructuring will affect its performance.,0.02084735594689846,0.010883916169404984,0.9682687520980835,neutral,0.009963439777493477
28,2016-01-26 09:24:00,"A week ago, the company said it would restructure some of its medical devices businesses in order to encourage innovation and address unmet needs of patients.",0.695858895778656,0.012666018679738045,0.2914750874042511,positive,0.6831928491592407
29,2016-01-26 09:24:00,"Johnson & Johnson hopes to generate as much as $1 billion in annual savings from the measures by the end of 2018, which could help immensely in supporting earnings growth.",0.9371272325515747,0.015564623288810253,0.04730817303061485,positive,0.9215626120567322
30,2016-01-26 09:24:00,"Investors were comfortable with Johnson & Johnson's results, sending the stock up 1% in pre-market trading after the announcement.",0.9483449459075928,0.024011507630348206,0.02764357253909111,positive,0.9243334531784058
31,2016-01-26 09:24:00,"With solid organic growth prospects, all Johnson & Johnson needs to do is to outlast the dollar's strength to see its true performance show up more clearly in its financials in 2016 and beyond.",0.8911331295967102,0.012694819830358028,0.09617193788290024,positive,0.8784382939338684
32,2016-01-26 09:24:00,"The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology.",0.07124034315347672,0.0912238135933876,0.8375357985496521,neutral,-0.01998347043991089
33,2016-01-26 09:24:00,And we think its stock price has nearly unlimited room to run for early in-the-know investors!,0.28927910327911377,0.013621804304420948,0.6970990896224976,neutral,0.2756572961807251
34,2016-01-26 09:24:00,"To be one of them, just click here .",0.08918054401874542,0.07975278049707413,0.8310666680335999,neutral,0.009427763521671295
35,2016-01-26 09:24:00,Dan Caplinger has no position in any stocks mentioned.,0.010743288323283195,0.037719108164310455,0.9515376091003418,neutral,-0.02697581984102726
36,2016-01-26 09:24:00,The Motley Fool recommends Johnson & Johnson and Procter & Gamble.,0.026330091059207916,0.02261643297970295,0.9510534405708313,neutral,0.0037136580795049667
37,2016-01-26 09:24:00,Try any of our Foolish newsletter services free for 30 days .,0.02325451746582985,0.013860778883099556,0.9628846645355225,neutral,0.009393738582730293
38,2016-01-26 09:24:00,"We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.",0.7942618727684021,0.015105843544006348,0.19063223898410797,positive,0.7791560292243958
39,2016-01-26 09:24:00,The Motley Fool has a disclosure policy .,0.016547108069062233,0.01730392687022686,0.9661489725112915,neutral,-0.0007568188011646271
40,2016-01-26 09:24:00,"Copyright © 1995 - 2016 The Motley Fool, LLC.",0.02603050321340561,0.02041543833911419,0.953554093837738,neutral,0.00561506487429142
41,2016-01-26 09:24:00,All rights reserved.,0.01556148286908865,0.01622452400624752,0.9682139754295349,neutral,-0.0006630411371588707
42,2016-01-26 09:24:00,The Motley Fool has a disclosure policy .,0.016547108069062233,0.01730392687022686,0.9661489725112915,neutral,-0.0007568188011646271
43,2016-01-26 09:24:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
